Effects of DPP4 Inhibition on COVID-19

• Status: Withdrawn
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Treatments: Insulin; Insulin, Globin Zinc; Linagliptin

Criteria

Inclusion Criteria:

• Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines

• Age ≥ 18

• Confirmed COVID-19

• Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore throat, myalgia, nasal congestion, diarrhea

• Moderate COVID-19 is defined as > 2 of the following in non-intubated patients: any symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with bilateral ground glass opacities or bilateral consolidations, SpO2 <90% up to 5L Nasal Cannula (NC)

• No additional signs or symptoms of severe COVID-19.

Exclusion Criteria:

• Type 1 Diabetes Mellitus (T1DM) diabetes, as per ADA guidelines

• History of Diabetic Ketoacidosis (DKA)

• History of acute pancreatitis

• Chronic or Acute Renal Failure with Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min/1.73 m2

Exclusion Criteria:

T1DM diabetes, as per ADA guidelines, History of DKA, History of acute pancreatitis; Chronic or Acute Renal Failure with eGFR < 30 ml/min/1.73 m2